1. Soft regulations in pharmaceutical policy making

   • Björn Wettermark
   • Brian Godman
   • Flora M. Haaijer-Ruskamp

   Current Opinion 06 August 2012 Pages: 137 - 147

   

2. Value-based insurance design in medicare

   • William E. Encinosa

   Current Opinion 06 August 2012 Pages: 149 - 154

3. Financial risk of the Biotech Industry versus the Pharmaceutical Industry

   • Joseph Golec
   • John A. Vernon

   Leading Article 06 August 2012 Pages: 155 - 165

   

4. Short-term cost and health consequences of duodenal levodopa infusion in advanced Parkinson’s disease in Sweden

   • Ivar Sønbø Kristiansen
   • Kerstin Bingefors
   • Dag Isacson

   Original Research Article 06 August 2012 Pages: 167 - 180

   

5. Economic evaluation of Sinfrontal®in the treatment of acute maxillary sinusitis in adults

   • Kyra C. Kneis
   • Afschin Gandjour

   Original Research Article 06 August 2012 Pages: 181 - 191

   

6. The economic value of primary prophylaxis using pegfilgrastim compared with filgrastim in patients with breast cancer in the UK

   • Zhimei Liu
   • Quan V. Doan
   • Robert Leonar

   Original Research Article 06 August 2012 Pages: 193 - 205